Dr. Yatindra Prashar, PhD

CEO, Symmetrix Pharmaceuticals

Yatindra is the CEO of Symmetrix Pharmaceuticals that is in the process of developing and commercializing a biologic wholly indigenously biologic: a Clot Specific Streptokinase discovered in India at the Institute of Microbial Technology.